Transatlantique Private Wealth LLC Invests $3.64 Million in AstraZeneca PLC $AZN

Transatlantique Private Wealth LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 47,410 shares of the company’s stock, valued at approximately $3,637,000. AstraZeneca makes up approximately 1.2% of Transatlantique Private Wealth LLC’s portfolio, making the stock its 20th largest holding.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. NewSquare Capital LLC increased its position in AstraZeneca by 149.3% in the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after purchasing an additional 218 shares during the last quarter. Rakuten Investment Management Inc. acquired a new stake in shares of AstraZeneca during the 3rd quarter valued at about $31,000. FSA Wealth Management LLC grew its stake in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares in the last quarter. VSM Wealth Advisory LLC acquired a new position in AstraZeneca in the second quarter worth approximately $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in AstraZeneca by 144.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after buying an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating for the company. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. HSBC reaffirmed a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research report on Wednesday, December 10th. Finally, TD Cowen reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Stock Performance

Shares of AZN opened at $204.45 on Monday. The company has a market capitalization of $317.09 billion, a PE ratio of 67.92, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $122.48 and a one year high of $212.71. The company’s fifty day moving average price is $124.40 and its 200 day moving average price is $97.76.

AstraZeneca Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s dividend payout ratio is presently 74.83%.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.